Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Validation survey of the impact of urinary incontinence (IIQ-7) and inventory of distress urogenital (UDI-6) - the short scales - in patients with multiple sclerosis.

Stievano LP, do Olival GS, da Silva RA, Toller VB, Carabetta EG, da Cunha ET, Moreira Rde J, Eloi M, Tilbery CP.

Arq Neuropsiquiatr. 2015 Jan;73(1):46-51. doi: 10.1590/0004-282X20140218. Epub 2015 Jan 1.

2.

Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.

Rocha AJ, Littig IA, Nunes RH, Tilbery CP.

Arq Neuropsiquiatr. 2013 Sep;71(9B):738-46. doi: 10.1590/0004-282X20130162. Review.

3.

Multiple sclerosis and herpesvirus interaction.

Olival GS, Lima BM, Sumita LM, Serafim V, Fink MC, Nali LH, Romano CM, Thomaz RB, Cavenaghi VB, Tilbery CP, Penalva-de-Oliveira AC.

Arq Neuropsiquiatr. 2013 Sep;71(9B):727-30. doi: 10.1590/0004-282X20130160. Review.

4.

Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis.

Olival GS, Cavenaghi VB, Serafim V, Thomaz RB, Tilbery CP.

Arq Neuropsiquiatr. 2013 Aug;71(8):516-20. doi: 10.1590/0004-282X20130081.

5.

The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.

Papais-Alvarenga RM, Vasconcelos CC, Alves-Leon SV, Batista E, Santos CM, Camargo SM, Godoy M, Lacativa MC, Lorenti M, Damasceno B, Damasceno A, Brum D, Barreira AA, GuimarĂ£es Rocha MS, Alvarenga H, Tilbery CP.

Mult Scler. 2014 Mar;20(3):374-81. doi: 10.1177/1352458513495580. Epub 2013 Aug 22.

PMID:
23970504
6.

Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity?

Fernandes AM, Duprat Ade C, Eckley CA, Silva Ld, Ferreira RB, Tilbery CP.

Braz J Otorhinolaryngol. 2013 Aug;79(4):460-5. doi: 10.5935/1808-8694.20130082. English, Portuguese.

7.

Genomic analysis of ERVWE2 locus in patients with multiple sclerosis: absence of genetic association but potential role of human endogenous retrovirus type W elements in molecular mimicry with myelin antigen.

do Olival GS, Faria TS, Nali LH, de Oliveira AC, Casseb J, Vidal JE, Cavenaghi VB, Tilbery CP, Moraes L, Fink MC, Sumita LM, Perron H, Romano CM.

Front Microbiol. 2013 Jun 26;4:172. doi: 10.3389/fmicb.2013.00172. eCollection 2013. Erratum in: Front Microbiol. 2013;4:345.

8.

Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A, Gama H, Tilbery CP, Rocha AJ, Flores J, Barkhof F, Seewann A, Palace J, Yousry T, Montalban X, Enzinger C, Fazekas F.

J Neurol. 2013 Aug;260(8):2016-22. doi: 10.1007/s00415-013-6918-y. Epub 2013 Apr 26.

PMID:
23620065
9.
10.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
11.

Clinical predictors of response to immunomodulators for multiple sclerosis.

Olival GS, Lima LC, Lima GP, Tilbery CP.

Arq Neuropsiquiatr. 2012 Jan;70(1):12-6.

13.

Validation of the "Six Step Spot Test" for gait among patients with multiple sclerosis in Brazil.

Pavan K, Tilbery CP, Lianza S, Marangoni BE.

Arq Neuropsiquiatr. 2010 Apr;68(2):198-204.

14.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
15.

Psychiatric disorders in multiple sclerosis patients.

Fazzito MM, Jordy SS, Tilbery CP.

Arq Neuropsiquiatr. 2009 Sep;67(3A):664-7.

16.

Meningioma growth during interferon beta-1A treatment for multiple sclerosis.

Gama HP, Rocha AJ, Silva CJ, Mendes MF, Veiga JC, Lancellotti CL, Andrade VP, Tilbery CP.

Arq Neuropsiquiatr. 2008 Jun;66(2B):402-4. No abstract available.

17.

Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases.

Jordy SS, Tilbery CP, Fazzito MM.

Arq Neuropsiquiatr. 2008 Mar;66(1):11-4. Erratum in: Arq Neuropsiquiatr. 2008 Jun;66(2A):292.

18.

[Multiple sclerosis: cross-cultural adaptation and validation of the modified fatigue impact scale].

Pavan K, Schmidt K, Marangoni B, Mendes MF, Tilbery CP, Lianza S.

Arq Neuropsiquiatr. 2007 Sep;65(3A):669-73. Portuguese.

19.

[Relation between fatigue and autonomic disturbances in multiple sclerosis].

Lebre AT, Mendes MF, Tilbery CP, Almeida AL, Scatolini Neto A.

Arq Neuropsiquiatr. 2007 Sep;65(3A):663-8. Portuguese.

20.

[Vestibular rehabilitation in patients with relapsing-remitting multiple sclerosis].

Pavan K, Marangoni BE, Schmidt KB, Cobe FA, Matuti GS, Nishino LK, Thomaz RB, Mendes MF, Lianza S, Tilbery CP.

Arq Neuropsiquiatr. 2007 Jun;65(2A):332-5. Portuguese.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk